COVID-19に対するHIPRAの候補ブースターワクチン接種の安全性と免疫原性を評価する第III相試験。
COVIDに対するワクチン接種を受けた成人における、SARS-CoV-2に対する組換えタンパク質RBD融合ヘテロ二量体候補(PHH-1V)によるブースターワクチン接種の安全性と免疫原性を評価する第III相、非盲検、単一アーム、多施設、試験-19.
This is a phase III clinical study to assess the safety, tolerability and immunogenicity of PHH-1V as a booster dose in healthy adult subjects vaccinated against COVID-19 with the Comirnaty, Spikevax, Vaxevria or Janssen vaccine.
調査の概要
詳細な説明
This is a phase III clinical study to assess the safety, tolerability and immunogenicity of PHH-1V as a booster dose in healthy adults vaccinated against COVID-19 with the Comirnaty, Spikevax, Vaxevria or Janssen vaccine at least 91 days before day 0. All the participants will receive a booster dose of the HIPRA's COVID-19 Vaccine and will be followed for 26 weeks or 52 weeks if they participate in the safety cohort, or the immunogenicity cohort, respectively.
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Milano
-
Milan、Milano、イタリア、20162
- Hospital de Niguarda
-
-
-
-
BARCELONA
-
Badalona、BARCELONA、スペイン、08916
- Hospital Germans Trias I Pujol
-
Barcelona、BARCELONA、スペイン、08035
- Hospital Vall Hebron
-
-
Barcelona
-
Barcelona、Barcelona、スペイン、08023
- Hospital HM Delfos
-
Barcelona、Barcelona、スペイン、08023
- Hospital Quironsalud Barcelona
-
Mollet del Vallès、Barcelona、スペイン、08100
- Hospital de Mollet
-
-
Girona
-
Girona、Girona、スペイン、17007
- Hospital Universitari Dr. Josep Trueta
-
-
Madrid
-
Madrid、Madrid、スペイン、28046
- Hospital Universitario La Paz
-
Madrid、Madrid、スペイン、28007
- Hospital Gregorio Marañón
-
Madrid、Madrid、スペイン、28050
- Hospital HM Sanchinarro
-
Madrid、Madrid、スペイン、28660
- Hospital HM Montepríncipe
-
Madrid、Madrid、スペイン、28223
- Hospital Quironsalud Madrid
-
Meco、Madrid、スペイン、28805
- Hospital Principe de Asturias
-
Móstoles、Madrid、スペイン、28938
- Hospital HM Puerta del Sur
-
-
Málaga
-
Málaga、Málaga、スペイン、29010
- Hospital Regional Universitario de Málaga
-
-
Spain
-
Barcelona、Spain、スペイン、17170
- Hospital Clinic de Barcelona
-
-
VIZCAYA
-
Barakaldo、VIZCAYA、スペイン、48903
- Hospital de Cruces
-
-
Valencia
-
Valencia、Valencia、スペイン、46010
- Hospital Clínico de Valencia
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Male or female, ≥ 16 years old at Day 0.
- Willing to provide consent indicating that she or he understands the purpose and potential risks and is willing and able to participate in the study and comply with all the study requirements and procedures.
- Have a recognized primary vaccination scheme recognized by the authorities with Comirnaty, Spikevax, Vaxevria or Janssen at least 91 days and preferably a maximum of 240 days before Day 0.
- If having an underlying illnesses must be stable and well-controlled according to the investigator judgment.
- Participant is willing to avoid receiving live attenuated vaccines (licensed) within 4 weeks before screening or after receiving any study vaccine, or other not live vaccines (licensed) within 14 days before and after receiving any study vaccine.
- Participant agrees not to donate blood, blood products and bone marrow at least 3 months before and after vaccination.
- Female participant of childbearing potential must have a negative pregnancy test on the on Day 0 prior to vaccination.
- Female participant of childbearing potential must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (hormonal contraception: oral, injectable or transdermal patch, intrauterine device, vasectomized partner, sexual abstinence or condom).
- Male participants must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (vasectomized participants, condom, sexual abstinence).
- Male participants must refrain from donating sperm for at least 28 days after day 0.
Exclusion Criteria:
- History of anaphylaxis to any prior vaccine.
- Previous severe SARS-CoV-2 infections that required >24 hous of hospitalisation.
- Participant received or plans to receive live attenuated vaccines within 4 weeks before and after day 0; or other not live vaccines within 14 days before and after day 0.
- Pregnancy or breast-feeding at screening or Day 0 or willingness/intention to become pregnant during the study.
- Having a clinically significant acute illness or fever (temperature ≥38º C (100.4ºF)) at screening or within 48 hours prior to Day 0.
- Participant had a surgery requiring hospitalization before vaccination and he/she has not received the hospital discharge at day 0; or has a surgery requiring hospitalization planned within 12 weeks after study vaccine administration.
- Having any active malignancy even if under treatment except for non-melanoma skin cancer, uterine cervical carcinoma, anal carcinoma, localized prostate cancer.
- Having ongoing severe and non-stable psychiatric condition likely to affect participation in the study.
- Having problematic or risk use of substances including alcohol that can compromise the study follow-up.
- Having a bleeding disorder or has any condition that in the opinion of the investigator contraindicates intramuscular injections.
- Having abnormal function of the immune system, except stable clinical conditions like controlled HIV.
- Having clinically significant and unstable cardiovascular, respiratory, hepatic, neurological, gastrointestinal, renal, or any other medical disorder judged by the investigator within 3 months before screening.
- Chronic or recurrent administration of systemic immunosuppressant medication.
- Having received immunoglobulins and/or blood-derived products 12 weeks prior vaccination (Day 0) or expects to receive them during the study.
- Having received any immunotherapy (monoclonal antibodies, plasma) aimed to prevent or treat COVID-19 within 90 days before day 0.
- Participation in any research involving an investigational product (drug, biologic, device) within 12 weeks prior to vaccination and during the study.
- Participant has donated ≥ 450ml of blood products within 12 weeks before screening.
- Participant has any medical condition and/or finding that in the investigator opinion might increase participant risks, interfere with the study or impair interpretation of study data.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Experimental: COVID-19 Vaccine HIPRA 40 ug/dose
COVID-19 Vaccine HIPRA, where subjects will receive one intramuscular injection of COVID-19 vaccine developed by HIPRA |
Intramuscular injection of 0,5 ml with 40 ug of recombinant PHH-1V |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events (Safety and tolerability)
時間枠:Day 7
|
Number, percentage, and characteristics of solicited local and systemic reactions through Day 7 after vaccination. |
Day 7
|
|
Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) (AEs)
時間枠:Day 28
|
Number, percentage, and characteristics of unsolicited local and systemic adverse events (AEs) through Day 28 after vaccination |
Day 28
|
|
Incidence of Serious Adverse Events (Safety and tolerability) (SAE)
時間枠:Day 365
|
Number and percentage of serious adverse events (SAEs) through the end of the study. |
Day 365
|
|
Incidence of Special Interest Adverse Events (Safety and tolerability) (AESI).
時間枠:Day 365
|
Number and percentage of adverse event of special interest (AESI) through the end of the study. |
Day 365
|
|
Incidence of Medically Attended Adverse Events (Safety and tolerability) (MAAEs)
時間枠:Day 365
|
Number and percentage of medically attended adverse events (MAAE) related to study vaccine through the end of the study. |
Day 365
|
|
Incidence of Adverse Events in laboratory parameters (Safety and tolerability)
時間枠:Day 365
|
Grade 3 and 4 changes from baseline in safety laboratory parameters at Days 14, 91 and 182 after vaccination. through the end of the study. |
Day 365
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Changes in the immunogenicity measured by pseudovirus neutralisation
時間枠:Day 365
|
Neutralisation titre against Wuhan and Omicron strains, and any other relevant VOC in the epidemiologic moment, measured as inhibitory concentration 50 (IC50) by a pseudovirion-based neutralisation assay (PBNA) and reported as reciprocal concentration for each individual sample and geometric mean titre (GMT) for descriptive statistics analysis at Baseline and at Days 14, 91, 182 and 365. |
Day 365
|
|
Changes in the immunogenicity measured by pseudovirus neutralisation
時間枠:Day 14
|
The geometric mean fold rise (GMFR) in neutralising antibody titre from baseline to Day 14. |
Day 14
|
|
Changes in the immunogenicity measured by means of total antibody against RBD
時間枠:Day 365
|
Binding antibodies titre measured for each individual sample and GMT for descriptive statistics analysis at Baseline and Days 14, 91, 182 and 365. |
Day 365
|
|
Changes in the immunogenicity measured by means of total antibody against RBD.
時間枠:Day 14
|
The geometric mean fold rise (GMFR) in binding antibody titre from baseline to Day 14. |
Day 14
|
|
Changes in the immunogenicity measured by means of total antibody against RBD
時間枠:Day 14
|
The percentage of subjects that after the booster dose have a ≥4-fold change in binding antibodies titre from Baseline to Day 14. |
Day 14
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To assess number of subjects with SARS-CoV-2 infections ≥14 days after PHH-1V booster.
時間枠:Day 365
|
Number and percentage of subjects with SARS-CoV-2 infections ≥14 days after PHH-1V booster according to COVID-19 infection criteria throughout the study duration. |
Day 365
|
|
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V. SARS-CoV-2 infections ≥14 days after PHH-1V booster.
時間枠:Day 365
|
Number and percentage of COVID-19 severe infections ≥14 days after PHH-1V booster and through the end of the study. |
Day 365
|
|
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V and hospital admissions SARS-CoV-2 infections ≥14 days after PHH-1V booster.
時間枠:Day 365
|
Number and percentage of hospital admissions associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study. |
Day 365
|
|
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V in ICU. SARS-CoV-2 infections ≥14 days after PHH-1V booster.
時間枠:Day 365
|
Number and percentage of intensive care unit (ICU) admissions associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study. |
Day 365
|
|
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V receiving noninvasive ventilation. SARS-CoV-2 infections ≥14 days after PHH-1V booster.
時間枠:Day 365
|
Number and percentage of noninvasive ventilation administration associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study. |
Day 365
|
|
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V causing death.
時間枠:Day 365
|
Number and percentage of deaths associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study. |
Day 365
|
|
To evaluate T-cell mediated responses against the SARS-CoV-2 S glycoprotein at Baseline and Day 14 in subjects who have received two doses of Vaxzevria vaccine and PHH-1V as a booster..
時間枠:Day 14
|
T-cell-mediated response to the SARS-CoV-2 S protein as measured by whole peripheral blood mononuclear cell (PBMC) stimulation by enzyme-linked immune absorbent spot (ELISpot) at Baseline and at Day 14. This analysis will be performed in 30 subjects. |
Day 14
|
|
To assess Th-1/Th-2 T-cell mediated responses against S protein at Baseline and Day 14 in subjects who have received two doses of Vaxzevria vaccine and PHH-1V as a booster.
時間枠:Day 14
|
CD4+/CD8+ T-cell response to the SARS-CoV-2 S protein as measured by in vitro PBMC stimulation by cytokine staining assays at Baseline and at Day 14. This analysis will be performed in 30 subjects. |
Day 14
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Teresa Prat、HIPRA SICENTIFIC S.L.U
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- HIPRA-HH-5
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。